Fig. 5

Astrocytic CXCL5 aggravated chronic ischemic WMI in a microglia-dependent manner. a, b Representative immunoblot bands of CXCR2 and quantification normalized to β-tubulin in primary cells of AST, NEUN, OL and MG. n = 3 per group. c Representative images for Iba-1 (green) and CXCR2 (red) double immunostaining in the primary microglia. Scale bar = 50 μm. d The rAAV-GFaABC1D-Cxcl5-mCherry was injected into the CC. Representative confocal images of mCherry expression within the astrocytes (GFAP). Scale bar = 50 µm (bottom). e QPCR analysis of Cxcl5 expression in the CC at 3 weeks after stereotaxic intracranial injection. n = 4 per group. f Experimental design. g, h Results of the OFT showing the time in the corner and center in four groups. n = 8–11 per group. i Results of Y-maze tests showing the spontaneous alternation percentage. n = 7–12 per group. j–m Results of the MWM test in four groups. j Escape latency during the acquisition phase (Days 1–5). Quantification of the crossing platform times (k), the time in target quadrant (l) and the swimming speed (m) of the probe test (Day 6). n = 7–10 per group. n–p Representative immunoblot bands (n) and quantification of MBP (o) and MAG (p) normalized to β-tubulin in the CC. n = 3 per group. q, r Representative images of LFB staining in CC and quantification of AOD. Scale bar = 200 μm (top) and 50 μm (bottom). n = 3 per group. s, t Representative images of immunostaining of MBP and quantification of immunostaining of MBP in the CC. Scale bar = 200 µm. n = 4 per group. All data were presented as the mean ± SEM. *p < 0.05, **p < 0.01, ns means no significance. oe-Cxcl5, overexpression of Cxcl5. Two-way ANOVA with Bonferroni's post hoc test for j. One-way ANOVA with Tukey’s post-hoc for the others